CHINA – Harbour BioMed, a Cambridge, MA, Rotterdam, NL, and Suzhou CN-based global, clinical stage biopharmaceutical company, completd its Series C financing of $102.8M.
The round was led by new investors, Hudson Bay Capital, followed by OrbiMed, Country Garden VC, GTJA Investment Group, Octagon Capital, and Sage Partners, with additional investment from existing investor Greater Bay Area Investment Fund. The round follows a $75 million Series B+ financing the company completed in March 2020. The company intends to use the funds to accelerate development of its portfolio of next generation biologics targeting cancer, immunologic diseases, and COVID-19. Led by Dr. Jingsong Wang, Founder, Chairman and CEO, Harbour BioMed is a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology, immunologic diseases, and COVID-19. The company is building its proprietary pipeline through internal R&D programs, collaborations with co-discovery and co-development partners and select acquisitions. Its internal discovery programs are centered around its two patented transgenic mouse platforms (Harbour Mice®) for generating fully human monoclonal antibodies: heavy chain only antibodies (HCAb), and H2L2 for conventional antibodies. Harbour integrates several next generation technologies including Harbour Mice®, HBICE™ immune engager, and the Beacon® Optofluidic System to accelerate its discovery efforts for novel molecules. The company also licenses the platforms to companies and academic institutions. 10/07/2020
